Targeting Ewing Sarcoma By Genetically and Epigenetically Modified Ex-Vivo Expanded NK Cells in Combination with NKTR-255 and Dinutuximab

Metastatic Ewing sarcoma (ES) has a dismal prognosis, largely due to therapy resistance within the tumor microenvironment (TME). NK cell resistance in solid tumors is mainly due to the small number and lack of specific targeting of NK cells, poor NK cell function and persistence, TGF β-mediated immune suppression, and inability of NK cells to infiltrate the tumor [1]. IL1RAP is a novel immunotherapy target highly expressed on ES cells [2]. Addition of TGFβ during NK expansion epigenetically reprograms NK cells (TGFβi-NK) and enhances NK-specific lysis of tumor cells [3].

Source: Biology of Blood and Marrow Transplantation - February 1, 2024 Category: Hematology Authors: Wen Luo, Hai-Feng Zhang, Wei Li, Hai Hoang, Yaya Chu, Ronan Gandhi, Wiebke Chemnitz, Janet Ayello, Renata Scopim-Ribeiro, Michael M Lizardo, Melanie Rouleau, Dimiter S Dimitrov, Dean Anthony Lee, Poul H Sorensen, Mitchell S. Cairo Tags: 107 Source Type: research